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Abst rac t
Allergic diseases are the most common chronic conditions lasting throughout the patient’s life. They not only cause 
significant deterioration in the quality of life of patients but also lead to significant absenteeism and reduced pro-
ductivity, resulting in very high costs for society. Effective and safe treatment of allergic diseases is therefore one of 
the main challenges for public health and should be carried out by all the specialists in family medicine, internists 
and paediatricians in collaboration with allergists, otorhinolaryngologists and dermatologists. Antihistamines are 
most commonly used in the treatment of allergies. Several dozen drugs are available on the pharmaceutical market, 
and their generic forms are advertised widely as very effective drugs for the treatment of allergic diseases. What is 
the truth? What are the data from clinical trials and observational studies? Are all drugs equally effective and safe 
for the patient? According to a panel of experts representing various fields of medicine, inappropriate treatment 
of allergies can be very risky for patients, and seemingly equally acting medications may differ greatly. Therefore,  
a panel of experts gathered the latest data from the entire scientific literature and analysed the latest standards 
and recommendations prepared by scientific societies. This paper provides a summary of these studies and high-
lights the importance for the patient of the proper choice of drug to treat his allergies.
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Which antihistamines should be chosen 
according to current standards  
and recommendations?
In the last few decades the incidence of allergic dis-
eases has grown to epidemic status. According to the 
current data, more than 600 million people suffer from 
allergic rhinitis worldwide, approximately 25% of them 
in Europe. In the ECAP trial (Epidemiology of Allergic 
Diseases in Poland) as many as 30% of respondents 
reported allergic rhinitis, less than 7% mentioned urti-
caria, but over 40% of patients had positive skin tests 
with common inhaled allergens (e.g. plant pollen, dust 
mites, mould and animal hair). Despite this huge number 
of patients, these data are frequently underestimated, 
since allergic diseases are generally believed to be trivial 
and non-hazardous. However, it has already been proven 
that allergic rhinitis, asthma and urticaria are associated 
with a significant socioeconomic burden all over the 
world – regardless of region, development level and fi-
nancial status. The total cost of allergic diseases brings 
both reduced quality of life and also direct costs of drugs 
and health services as well as indirect social costs such 
as the absence from work; it also decreases productivity 
and concentration and generates learning disorders and 
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concomitant diseases. As allergic diseases occur mainly 
in the young population (which supports the senior popu-
lation), their consequences are much more costly than 
those of diabetes, coronary heart disease or myocardial 
infarctions. In the USA alone, the costs of allergic rhini-
tis morbidity are estimated at over 25 billion dollars per 
year, of which approximately a half consists of indirect 
costs, resulting from insufficient disease control. In light 
of these studies it is not difficult to notice multidirec-
tional benefits from effective management of allergic 
diseases, which improve both the patients’ activity, pro-
ductivity and quality of life and ultimately decrease the 
financial burden of healthcare systems. Efficient therapy 
of the most common allergic diseases is based mainly on 
oral antihistamines which are administered simply and, 
as a result, have the best compliance among the drugs 
recommended for the treatment of allergic rhinitis.
Histamine plays an important role in human physi-
ology, influencing immunoregulation of the acute and 
chronic inflammatory response through 4 different types 
of receptors, called H1, H2, H3, and H4. Drugs classified in 
the first generation of antihistamines (sometimes called 
“classical” antihistamines) act non-selectively. Apart from 
all histaminic receptors they also block muscarinic, ad-
renergic (or adrenoreceptors) and dopaminergic recep-
tors, causing cardiovascular, urinary and gastrointestinal 
adverse reactions. High lipophilicity and consequently 
easy crossing of the blood-brain barrier additionally 
intensify the most dangerous adverse events from the 
central nervous system, including drowsiness, decreased 
concentration, vigilance and psychomotor efficiency as 
well as reduced ability to learn and memorize, which is 
not related to sedation. However, in histamine-depen-
dent allergic diseases the most important role is played 
by the H1 receptor, whose stimulation by histamine re-
sults in e.g. constriction of smooth muscles (obturation of 
inhalatory tract), increased permeability of endothelium 
(oedema) and stimulation of sensory nerves and cough 
receptors (pruritus, sneeze attacks, rhinorrhoea). There-
fore, the discovery of compounds selectively acting on 
H1 receptors, currently called second generation drugs, 
could be considered the greatest breakthrough during 
more than 70 years of the history of antihistamines (Fig-
ure 1). On top of the high efficacy, the most important 
feature of these drugs is the incomparably better safety 
profile: some of them have the same (or even lower) 
number of adverse reactions as placebo. Due to the selec-
tive mechanism of action, low penetration of the central 
nervous system (CNS) and lack of interaction with adren-
ergic, muscarinic and dopaminergic receptors, the second 
generation drugs are devoid of the majority (if not all) 
of the side effects mentioned above; however, some of 
them could cause other serious adverse reactions, includ-
ing body mass gain, inter-drug interactions or potentially 
life-threatening cardiotoxicity (in the majority of coun-
tries, these preparations have been withdrawn from the 
market) (Figure 2). Due to selective antagonism with H1 
receptors, these drugs are highly effective in reduction 
of allergic rhinitis and urticaria symptoms, and the wide 
therapeutic index makes it possible to use them in very 
high doses without any concerns related to overdosing 
toxicity, which with the first generation drugs could lead 
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to consciousness disturbances, coma, respiratory dis-
tress, and even death.
The described characteristics and easy usage as well 
as affordable price led to the inclusion of the second gen-
eration antihistaminic drugs in all global and local recom-
mendations as the drugs of choice in all forms of allergic 
rhinitis and urticaria. The most frequently cited are ARIA 
(Allergic Rhinitis and its Impact on Asthma) guidelines, 
which discusses pharmacotherapy and presents the 
second generation anti-H1 drugs in the first place, rec-
ommending them in all adults and children [1]. Addition-
ally, they highlight that the first generation drugs are 
not recommended wherever newer drugs are available. 
Almost the same recommendations could be found in 
the current EAACI/GA(2)LEN/EDF/WAO guidelines of ur-
ticaria management, in which non-sedative second gen-
eration antihistamines are recommended not only as the 
first but also as the second line drugs (after a maximum 
4-fold dose increase in case of lack of efficacy of the stan-
dard dose administered for 2 weeks).
In light of the presented guidelines it is quite clear that 
non-sedative antihistamines are the backbone of allergic 
diseases treatment. However, the number of available 
drugs brings a dilemma: which drug should be chosen? 
Which criteria should be recognized in the decision-
making process? Patients have different expectations, 
concomitant diseases and symptoms intensity, so the an-
swer is not obvious, and each patient should be treated 
individually. From an average allergic perspective, the most 
important criteria of the drug choice are efficacy and price 
but – considering that not all second generation drugs are 
totally side effect-free in term of sedation, and their influ-
ence on ability to drive and learn is not commonly known 
by people – the safety profile and side effects should be 
especially taken into consideration in the drug selection 
process. Moreover, there are more and more patients in 
allergology practice treated due to concomitant chronic 
diseases, so inter-drug interactions are also an important 
factor, which should be taken into consideration treating 
allergic rhinitis and urticaria [2]. Thus, drugs which are not 
metabolized in the liver should be chosen.
As the second generation antihistamines available in 
Poland have comparable efficacy in controlling allergic 
rhinitis and urticaria symptoms, the most important fac-
tor distinguishing them seems to be the influence on the 
CNS and the safety of this therapy. Hence, when prescrib-
ing an anti-H1 drug according to recommendations we 
should first take into consideration the preparations with 
the smallest possible sedative effect, wide therapeutic 
index, beneficial pharmacokinetics and the lowest num-
ber of inter-drug interactions (Figure 3). This selection 
is of special importance in patients whose professions 
require concentration (such as driving), in which even 
a small sedative effect could lead to serious conse-
quences (Figure 4). Here, we present the expert opinion 
regarding the role of bilastine in the management of 
allergic rhinitis and urticaria as a non-sedative second 
generation antihistaminic drug of an extremely favour-
able safety profile which does not influence the ability 
to drive vehicles and other machines, does not have any 
interactions with other drugs or alcohol, and (in allergic 
patients) decreases drowsiness even when compared to 
placebo [3, 4].
The newest antihistamines in the management 
of allergic rhinitis and allergic conjunctivitis
Allergic rhinitis is a complex of clinical symptoms 
caused by an inflammatory reaction including antibod-
ies immunoglobulins E (IgE) targeting sensitizing aller-
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gens. The clinical symptoms of allergic rhinitis include 
rhinorrhea, nasal congestion, itchy nose and sneezing [5]. 
These symptoms are recurrent and intensify after contact 
with the allergen. Sometimes the patient’s complaints 
include concentration disturbance, fatigue, or snoring.
Allergic conjunctivitis frequently coincides with aller-
gic rhinitis. Eye symptoms, including watering, redness 
and itching, usually develop before nasal symptoms.
Allergic rhinitis and allergic conjunctivitis are concomi-
tant so frequently that in many countries they are defined 
as one condition (e.g. allergic rhinoconjunctivitis).
The symptoms of allergic rhinitis significantly reduce 
quality of life; they adversely influence social life and 
decrease performance in learning and work. Untreated 
(or undertreated) allergic rhinitis (incompatible with rec-
ommendations) could lead to complications in the lower 
respiratory tract, paranasal sinuses and ears.
Figure 3. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treat-
ment of seasonal allergic rhinitis (somnolence) [3]
Bilastine 20 mg 
(N = 227)
4 (1.8%)








Incidence of treatment emergent adverse events (AEs) (%)
Analysis based on c2 test; pair-wise comparisons: ‡bilastine vs. cetirizine: p = 0.01; §placebo vs. cetirizine: p = 0.01/bilastine vs. 
cetirizine; p < 0.01; #placebo vs. bilastine: p = 0.03/bilastine vs. cetirizine p < 0.01; *bilastine vs. cetirizine p = 0.01.
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Figure 4. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treat-
ment of seasonal allergic rhinitis (fatigue) [3]
Incidence > 2% in any treatment group.
Analysis based on c2 test; pair-wise comparisons: ‡bilastine vs. cetirizine: p = 0.01; §placebo vs. cetirizine: p = 0.01/bilastine vs. 
cetirizine; p < 0.01; #placebo vs. bilastine: p = 0.03/bilastine vs. cetirizine p < 0.01; *bilastine vs. cetirizine p = 0.01.
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In the ECAP trial the incidence of allergic rhinitis was 
assessed and attributed to 22.4% of the population un-
der research [6].
According to triggering allergens and duration of ex-
posure time, allergic rhinitis was previously divided into 
seasonal, perennial and occupational. In 2001, an inter-
national workgroup proposed an ARIA statement with 
a new classification of allergic rhinitis based on dura-
tion of clinical symptoms. They distinguished periodic 
allergic rhinitis (with symptoms not shorter than 4 days 
per week or shorter than 4 weeks) and chronic allergic 
rhinitis (with symptoms lasting for more than 4 days per 
week and longer than 4 weeks) [5]. Depending on the 
intensity of symptoms, allergic rhinitis could be split into 
mild and moderate/severe. 
The choice of drugs for allergic rhinitis treatment is 
based on its intensity level and clinical symptoms. In 
each case, allergen-specific immunotherapy should be 
considered.
Updated recommendations indicate that the second 
generation antihistamines (without a sedative effect) and 
local glucocorticosteroids are the main drugs used in aller-
gic rhinitis management. Although the second generation 
antihistamines reduce itching and sneezing highly effi-
ciently, glucocorticosteroids effectively reduce nasal con-
gestion, which is a symptom of delayed allergic reaction.
According to the recommendations published in ARIA 
and PoSLeNN (Polskie Standardy Leczenia Nieżytów 
Nosa) documentation, the basic treatment of patients 
with any form of chronic allergic rhinitis as well as in 
moderate and severe periodic allergic rhinitis should 
be based on local glucocorticosteroids [7, 8], and oral 
antihistamines should complement allergic rhinitis 
therapy. The use of oral antihistamines is specifically 
justified in patients with concomitant extra-nasal symp-
toms: pruritus, eye watering and redness, symptoms 
from the mouth and pharyngeal mucosa as well as skin 
signs. The second generation oral antihistamines are 
indicated, including those without a sedative effect. 
Allergic rhinitis involves the nasal cavity, and it is also 
a systemic disease, so the systemic treatment would re-
lieve all relevant symptoms of allergic inflammation.
The nasal cavities should be investigated before lo-
cal administration of glucocorticosteroids. In the case 
of very tight nose congestion local drugs are ineffective 
because they could not be delivered to the entire nasal 
mucosa. Patients with anatomical variations (e.g. nasal 
septum deviation, hyperplasia of nasal turbinate) have 
additional restrictions with administration of intranasal 
drugs. Treatment with intranasal glucocorticosteroids 
could be associated with adverse reactions (burning sen-
sation, pain, bleeding) which could discourage patients 
from taking such drugs. The full effect of the drug could 
be apparent at 5–7 days of its administration; however, 
the relief of symptoms could be observed within a few 
hours after the administration of the second generation 
antihistamines. This is very important in patients with 
periodic allergic rhinitis, when the duration of the con-
dition is shorter than the onset of action of intranasal 
glucocorticosteroids. Physicians and patients are also 
discouraged by the quite widespread phobia of steroids. 
For these reasons, many patients prefer to use oral drugs 
instead of intranasal drugs. Therefore, the therapy with 
the second generation antihistamines seems to be more 
beneficial. Favourable tolerability and safety profile of the 
drug should always be considered when taking a deci-
sion on the choice of an antihistamine. Bilastine is the 
most modern drug in this group, and meets the criteria 
mentioned above.
In a randomized, double-blinded, placebo-controlled 
clinical trial Horaka et al. [9] compared in Vienna Chal-
lenge Chamber conditions outside the pollen season the 
efficacy of bilastine, cetirizine and fexofenadine in reliev-
ing nasal and extra-nasal (mainly ocular) symptoms of 
allergic rhinitis. They found that bilastine in a dose of 
20 mg is effective in relieving the nasal and extra-nasal 
symptoms of seasonal allergic rhinitis. Bilastine is char-
acterized by fast onset of action already at one hour after 
administration, and the effect lasted over 26 h. Bilastine 
is more effective when compared to placebo in relieving 
allergic rhinitis symptoms, and its efficacy in relieving 
the nasal symptoms of allergic rhinitis was comparable 
with cetirizine. Compared to fexofenadine in the dose of 
120 mg, bilastine in the dose of 20 mg is significantly 
more effective in relieving nasal symptoms of seasonal 
allergic rhinitis in the period between the 22nd and 26th h 
after its administration. 
In another randomized, double-blinded clinical trial, 
the efficacy of bilastine in the dose of 20 mg and cetiri-
zine in the dose of 10 mg was compared with placebo 
in 681 patients from 61 European sites [3]. The results 
showed that bilastine in the dose of 20 mg administered 
once a day for 2 weeks was more effective than placebo 
in relieving the symptoms of seasonal allergic rhinitis. 
Bilastine showed the same efficacy as cetirizine in relief 
of nasal and extra-nasal symptoms of allergic rhinitis for 
the entire 14 days of treatment. Bilastine decreased the 
intensity of patient’s discomfort associated with allergic 
rhinitis comparably to cetirizine.
In a randomized, double-blinded, placebo-controlled 
clinical trial bilastine (20 mg), desloratadine (5 mg) and 
placebo were administered to 721 patients at the age be-
tween 12 and 70 years with seasonal allergic rhinitis [10]. 
It was found that bilastine administered for 2 weeks in 
a dose of 20 mg efficiently relieved the symptoms of sea-
sonal allergic rhinitis. Additionally, bilastine significantly 
reduced the symptoms of allergic rhinitis as compared to 
placebo. Efficacy of bilastine and desloratadine in relief of 
nasal and extra-nasal symptoms of allergic rhinitis after 
7 and 14 days was similar. Comparably to desloratadine, 
bilastine improved the quality of life in patients with al-
lergic rhinitis.
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In a randomized, double-blinded, placebo-controlled 
clinical trial Sastre et al. [11] compared the efficacy of bi-
lastine and cetirizine in the treatment of allergic rhinitis. 
It was found that the efficacies of bilastine and cetirizine 
are similar and significantly higher when compared to 
placebo. Additionally, bilastine was found to be effective, 
safe and well tolerated in 12 months of treatment.
To conclude, it should be stated that bilastine is an 
effective drug in relieving nasal and ocular symptoms 
of allergic rhinitis, and it shows fast and durable activ-
ity after the administration of a single dose. The efficacy 
of bilastine is comparable with the efficacy of cetirizine, 
desloratadine and fexofenadine in relieving the symp-
toms of allergic rhinitis. Bilastine significantly improves 
quality of life in patients with allergic rhinitis. 
The newest antihistaminics in the management 
of urticaria
Urticaria has always been related to the antihistaminic 
treatment. It results from the fact that histamine is one 
the basic mediators responsible for the development of 
all the main symptoms of the disease, such as erythema, 
oedema, pruritus/itching and burning sensation. However, 
nowadays it has become evident that besides histamine a 
very wide panel of various mediators is also involved in ur-
ticaria clinical appearance, and both synthesis and release 
of these mediators are dependent on different, sometimes 
complex etiologic and/or triggering factors, which unfortu-
nately often remain unclear [12, 13].
Depending on the duration of clinical symptoms (the 
time since the first episode of urticarial wheals), urticaria 
can be classified as acute (up to 6 weeks) or chronic (over 
6 weeks). From the clinical point of view, causes and co-
existing triggering factors are highly difficult to define in 
patients with chronic spontaneous urticaria. Generally, 
autoimmune (autoreactive) or infection-related causes 
(focuses of latent infections, Helicobacter pylori, parasitic 
infestations, etc.) may be identified. However, there are 
still remaining clinical cases which need to be classified 
as chronic spontaneous urticaria of an unknown cause. 
Within this group of patients urticarial wheals (often ac-
companied by symptoms of angioedema) erupt spontane-
ously, without either any specific or predictable cause or 
triggering factor.
The current urticaria classification was prepared, pre-
sented and published in 2014 by a group of experts rep-
resenting international scientific societies in allergology 
and dermatology (Table 1) [14].
The general rules related to the management of 
chronic urticaria were also presented in the guidelines 
published in 2014 (Figure 5). Thus, in case of the lack of 
efficacy of the classical dose of a modern antihistaminic, 
the dose should be increased, sometimes even up to 
four-fold. If the treatment is still ineffective, it should be 
in addition to the high dose of the new generation anti-
histaminic supplemented with cyclosporine A, omalizum-
ab or montelukast. Obviously, the exchange of a modern 
antihistaminic for another medication of the same group 
(obviously of different pharmacological characteristics) 
should also be individually considered. Moreover, it 
should be pointed out that evidence of the safety and 
efficacy of high dose-treatment with antihistaminics has 
been proven and is available only for some selected mod-
ern antihistamines, and therefore potential medications 
of choice should be limited to this group only. Obviously 
if exacerbations in the course of urticarial and/or angio-
edema symptoms develop, a short-term (up to 1 week) 
systemic treatment with glucocorticosteroids is possible. 
It should be highlighted that systemic glucocorticoste-
roids should never be regarded as the therapy of choice 
in patients with chronic spontaneous urticaria. Unfor-
tunately, there are still many doubts about the proper 
understanding and clinical implementation of guidelines 
regarding diagnosis and therapy of chronic urticaria. It 
has been highly surprising to find out that only 30% of 
physicians responsible for treatment of urticarial patients 
Table 1. Classification of chronic urticaria subtypes (presenting with wheals, angioedema, or both) (based on [14])
Subtypes of chronic urticaria
Chronic spontaneous urticaria Induced urticaria
Spontaneous eruption of wheals, angioedema or both 
symptoms ≥ 6 weeks of known or unknown cause 
Symptomatic dermographism (urticaria factitia)
Cold urticaria (contact cold urticaria)
Delayed pressure urticaria (pressure urticaria)
Solar urticaria
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have actually familiarised themselves appropriately with 
that important paper. 
Another exceptionally important fact which should be 
underlined (and which was also reflected in the current 
guidelines) is that in the treatment of urticaria two or more 
antihistamines should never be combined. For example, it 
is a grave error to recommend two tablets of bilastine in 
the morning, and 1–2 tablets of levocetirizine in the eve-
ning. Unfortunately, despite previous guidelines from the 
year 2009 and the new updated version, such mistakes still 
occur in the daily clinical practice. It should be strongly un-
derlined that this type of approach is simply wrong: higher 
efficacy of a combined antihistaminic treatment (2 or more 
antihistaminics combined together) has never been con-
firmed; and finally the risk of combined adverse reactions 
to the administered drugs is significantly high.
Bilastine is a modern antihistaminic, which was thor-
oughly and specifically evaluated in the treatment of pa-
tients with chronic spontaneous urticaria related to dif-
ferent causes as well as in patients with chronic induced 
urticaria (e.g. cold-induced chronic urticaria). There is 
comprehensive documentation available regarding both 
the efficacy and safety of this medication administered 
in high doses and, even more importantly, there is also 
well-documented in vivo (microdialysis of the skin) anti-
inflammatory activity of bilastine. The studies performed 
by Zuberbier et al. provide the best evidence [15–18].
From the clinical standpoint, it is also very important 
to remember that the old generation of antihistaminics 
is absolutely not indicated in the treatment of chronic 
spontaneous urticaria, and only in case of acute urticaria 
and/or angioedema if parenteral treatment is necessary 
may this group of antihistaminics be administered. How-
ever, in such cases systemic glucocorticosteroids should 
be concomitantly required. It is considered to be the pre-
ventive treatment in terms of possible development of 
a systemic anaphylactic reaction [19].
To summarize, chronic spontaneous urticaria still re-
mains a difficult challenge for us. Characterized by an 
often unclear and highly complex aetiopathogenesis, it 
requires treatment based on both wide clinical experi-
ence and knowledge of current guideline. The proper, 
selective choice of modern antihistaminic medication 
should be based on robust knowledge and available 
evidence regarding both efficacy and safety of high-dose 
antihistaminic treatment. 
Cardiovascular safety of antihistamines
The newest antihistamines of the second genera-
tion currently registered and used in Poland have rela-
tively high cardiovascular safety. It results from their 
relatively high receptor selectivity and use of centralized 
electrocardiography (ECG) evaluation by cardiologists in 
all phases of clinical trials with the new drugs. Finally, 
this leads to early elimination of drugs which (albeit to 
a small extent) influence ion channels. The review of the 
whole published literature showed that to date only 171 
publications have addressed the problem. Astemizole 
was one of the first drugs which led to more interest in 
the influence of antihistamines on the heart. It is inter-
esting that the first published data were favourable [20]. 
Only the later clinical studies in human and experimental 
animal studies indicated that the drug had the ability of 
strongly inhibiting potassium channels in cardiac muscles 
cells. The consequence of that process is delayed repo-
larization of ventricular muscle cells, which is clinically 
presented as the prolongation of QTc interval. Its direct 
result is a significant increase of risk of life-threatening 
ventricular arrhythmias. However, the clinical data show 
that this phenomenon is observed mainly in the case of 
administration of high doses, exceeding registered and 
recommended doses, metabolic interactions or in spe-
cific situations, e.g. hypoxia of cardiac muscle cells [21–
28]. The drugs mentioned above were withdrawn from 
the market due to relatively high risk of cardiovascular 
adverse events [26–28]. Any concerns whether blockade 
of potassium channels is an antihistamines class effect 
were quickly dispelled by indicating that this process 
is not associated with drugs other than the ones men-
tioned above [21, 29, 30]. Since then, in clinical trials with 
all antihistamines their clinical features regarding the in-
fluence on QTc interval have been meticulously assessed.
New guidelines regarding treatment of chronic ur-
ticaria slightly changed our view on the potential and 
actual safety of antihistamines. Established manage-
ment including increasing the standard dose of the anti-
histamine to a four-times higher dose could potentially 
prolong the QTc interval. The majority of antihistamines 
have not been subjected to clinical studies with those 
doses conducted in adequately large populations. More-
over, after the publication of the guidelines there were 
Figure 5. Recommended treatment algorithm for chronic 
spontaneous urticaria [14] 
First line: 
modern second generation antihistamines
Second line: 
increase dosage up to fourfold of modern 
second generation antihistamines
Third line:
add on to second line: omalizumab or ciclosporin A 
 or montelukast. Short course (max. 10 days) of 
corticosteroids may also be used at all times if 
exacerbations demand this
If symptoms persist after 
2 weeks
If symptoms persist after 
1–4 further weeks
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also additional publications that showed that in some 
cases and for some antihistamines a four-times higher 
dose could be inefficient – and possibly in such cases 
even a six-fold higher dose should be used in the treat-
ment of chronic urticaria. There have been no published 
clinical trials addressing the problem of cardiovascular 
safety of antihistamines in doses six times higher than 
standard doses. Relatively well-designed studies regard-
ing cardiovascular safety were conducted with bilastine. 
This drug administered in doses from 20 mg up to 100 mg 
(a five-fold higher dose than registered) in 30 healthy vol-
unteers did not influence either the morphology of the 
ECG signal or the QTc interval [31]. The QTc prolongation 
did not exceed 5.0 ms (95% CI: 2.0–8.0) for high doses of 
the drug. Moreover, when bilastine was administered in 
combination with ketoconazole 400 mg, the QTc interval 
and morphology of the ECG signal were similar to pla-
cebo [31]. Those clinical trials were conducted according 
to recommendations of E14 – the International Confer-
ence of Harmonisation (ICH) [31]. None of the conducted 
clinical trials showed any influence of bilastine on the 
morphology of the ECG signal and QTc interval. Thus, it 
could be stated that the cardiovascular safety of bilastine 
is very high, and the influence of the drug on morphology 
of the ECG signal and cardiac muscle repolarization is the 
same as that of placebo [10, 15, 32–44].
Use of antihistamines in treatment of viral 
infections of the upper respiratory tract
Taking into consideration the pathophysiology of up-
per respiratory tract infection, the non-sedative antihista-
mines of the second generation could have symptomatic 
activity, improving quality of life of those patients. This 
question has been relatively rarely studied, and to date 
fewer than 100 articles on this topic have been published. 
The results of a meta-analysis of available clinical studies 
showed that drugs from this therapeutic class could have 
important symptomatic activity during the initial period, 
especially in the first days of infection [45]. They are ef-
fective mainly in adult patients [45]. It seems that apart 
from the relatively weak effect blocking the H1 receptor, 
the extra-receptor anti-inflammatory activity could be 
even more important. For example, bilastine, inhibiting 
release of IL-6 and IL-8, could potentially have some ef-
fect [15]. Obtaining convincing results of clinical trials and 
formulating unambiguous conclusions require further 
in vivo and in vitro studies. 
Past, present and future of antihistamines. 
What should be considered from the 
pharmacologist’s perspective?
The 21st century gives us the possibility of the practi-
cal use of personalized pharmacotherapy, which includes, 
in the broad sense, safety of therapy as one of the most 
important criteria of drug choice. This is a direction of evo-
lution and development of particular therapeutic groups, 
and the best examples are some antihistamines, which are 
characterized by high effectiveness and also by an optimal 
safety profile. The latter factor includes the reduction of 
the risk of adverse events and also the reduction of the 
risk of interactions when antihistamines are administered 
as a component within a multi-drug therapy.
The introduction of the second generation drugs 
brought many benefits for patients with indications for 
these drugs. The biggest progress was seen according to 
the possibilities of adjusting the drug to the individual 
patient’s need with additional reduction of the number 
and intensity of adverse events, what directly translates 
into patient’s compliance. Contrary to the first genera-
tion drugs, the second generation shows high selectivity 
against type 1 histamine receptors with minimal or lack 
of affinity to other groups of receptors, which does not 
intensify the therapeutic effect but increases the risk of 
occurrence of adverse events.
Low (or even a lack of) affinity to other groups of re-
ceptors, such as muscarinic, α1 adrenergic and dopami-
nergic, limits the occurrence of adverse events, e.g. visual 
disturbances, dry mouth, sedative effect, and difficulties 
in passing urine, which all reduce the quality of life. As 
it has been previously mentioned, they frequently cause 
incompliance, and even treatment interruption, which 
translates into treatment efficacy and final outcomes.
Lipophilicity and distribution volume of the second 
generation drugs are not so large as for the first genera-
tion drugs, which prevents their crossing of the blood-
brain barrier and induction of adverse events in the CNS 
including excessive sedation, drowsiness, fatigue and 
significant reduction of psychomotor efficiency.
Lack of influence on central H1 receptors prevents ap-
petite increase and weight gain. This is especially impor-
tant in patients with diabetes, hypercholesterolaemia or 
overweight patients because body mass gain increases 
insulin resistance and the likelihood of related complica-
tions.
Very beneficial changes in the mechanism of action 
of the antihistamines of the second generation led to the 
situation in which they are the preferred group of drugs 
in clinical practice.
Currently, there are very few or even no indications 
for the first generation drugs. They are used for a short 
period as components of complex drugs administered in 
the symptomatic treatment of cold and influenza, where 
they act mainly as anticholinergics. In patients with rhi-
nitis with concomitant nasal congestion α1 adrenolytic 
activity could even be harmful.
Unquestionably, the second generation drugs form 
a category that is not homogeneous. Their pharmacoki-
netic and pharmacodynamic characteristics determine 
their features, which are frequently criteria of choice.
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It should be remembered that allergic reaction and 
concomitant symptoms very often coexist with other 
acute or chronic diseases. Thus, during administration of 
antihistamines the high risk of both pharmacokinetic and 
pharmacodynamic interactions should be considered. 
From a practical point of view, the pharmacokinetic in-
teractions are the most important in this group of drugs, 
and they take place during the metabolism stage via iso-
enzymes of cytochrome P450.
Therefore, the risk of adverse interactions unques-
tionably increases when antihistamine is metabolized 
via cytochrome P450. To prevent inter-drug interactions 
and their clinical consequences and the need for treat-
ment modification, drugs not metabolized via CYP450 
should be chosen. One such drug is bilastine. It should 
be highlighted that one of the most important criteria of 
antihistamine choice is the risk of interaction in multi-
drug therapy, also taking into consideration that allergic 
diseases and asthma are chronic diseases, which espe-
cially increases polypragmasia risk. Available pharmaco-
epidemiological studies indicate that the risk of exces-
sive polytherapy increases four to five times in patients 
with allergic diseases. Other observations supplement 
this hypothesis and confirm that the risk of excessive 
polytherapy is especially high during treatment of car-
diovascular disease, analgesic treatment and therapy of 
allergic diseases.
Additionally, it is worth remembering that there is 
a notable risk of interactions within the antihistamine 
group, which is associated with characteristics of par-
ticular drugs.
Bilastine is one of the newest drugs in the second 
generation antihistamines. It has a very interesting ac-
tivity profile because bilastine is a new molecule, with 
its own pharmacological characteristics. It should be 
underlined, as there are many available antihistamines 
after “metamorphosis”, which are metabolites or isolated 
enantiomers of basic compounds, e.g. levocetirizine and 
desloratadine. As enantiomers and metabolites often 
maintain the pharmacodynamic specificity of a native 
drug, this “metamorphosis” does not always bring signif-
icant benefits associated with drug activity. Hence, this 
could have a very low influence on decreasing the risk 
of interactions, especially pharmacokinetic, which could 
occur with other concomitantly administered drugs. 
Bilastine is a drug of high affinity to the H1 receptor. 
It does not bind to muscarinic receptors and does not 
have any sedative activity. Bilastine does not show any 
adverse interactions with other concomitant drugs as it 
does not undergo liver metabolism. The drug is excreted 
with faeces in an unchanged form, but a small portion of 
it is excreted with urine. Bilastine dosage should not be 
modified in patients with renal and hepatic insufficien-
cies. It could be safely taken by patients driving vehicles, 
and it does not influence the QTc interval in the ECG 
record, which significantly improves the cardiovascular 
safety profile as compared to the class.
Concomitant administration of drugs influencing 
activity of glycoprotein P or polypeptides transporting 
organic anions or their substrates could change the con-
centration of bilastine. Administration of ketoconazole 
or erythromycin at the same time increases bilastine 
area under the curve (AUC) and Cmax, whilst diltiazem 
increases the drug plasma concentration. Ritonavir and 
rifampicin could decrease the bilastine plasma concen-
tration.
Bilastine does not intensify the depression of the CNS 
caused by lorazepam or alcohol-induced disturbances. In 
the case of other antihistamines, especially penetrating to 
the CNS, their intensification of central depression should 
be considered. Tricyclic antidepressants and other cholino-
lytic drugs intensify the anti-muscarinic effect.
Cholinolytic activity of antihistamines weakens the 
effect of mucolytic and mucokinetic drugs, so in patients 
who use them it is recommended to choose an antagonist 
of the H1 receptor, which is deprived of anti-muscarinic 
activity – and bilastine is such a drug. Antihistamines eas-
ily penetrating to the CNS intensify sedative activity and 
increase the risk of adverse events occurring concomi-
tantly with administration with phenothiazines, fenspiride, 
benzodiazepines and antidepressants with sedative activ-
ity (mianserin, mirtazapine, trazodone). During bilastine 
administration, such interactions are of no clinical impor-
tance. 
In patients driving motor vehicles and mechanical 
machines, the sedation and prolonged reaction time are 
a very important problem. It should be remembered that 
during long-term administration of sedative antihista-
mines the phenomenon of reduction of psychomotor 
efficacy is not decreased. However, this adverse event is 
changed qualitatively. Practically, it means that patients 
do not have any individual feelings of prolonged reaction 
time and sedation, but it does not mean that a patient is 
fully efficient.
Using antihistamines with sedative activity is part of 
the bigger problem of road accidents, which is connected 
to the public health area. Every fifth accident is caused by 
patients taking drugs which could impair their psychomo-
tor efficacy. There are some publications comparing im-
pairment of psychomotor efficacy after administration of 
antihistamines of the old generation to alcohol-induced ef-
fects. For instance, the effect after taking clemastine is the 
equivalent of consumption of 0.8 g/l of alcohol. Bilastine 
does not produce such impairment of psychomotor effi-
cacy, which is otherwise possible during administration of 
cetirizine (the most frequently used drug in Poland). There 
are more details on this topic in the literature presenting 
a problem of adverse events in clinical practice. The anti-
histamines of the first generation as well as cetirizine, be-
ing a metabolite of hydroxyzine, could lead to reduction of 
attention and vigilance, contributing to impairment of psy-
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chomotor efficacy. Nevertheless, contrary to the common 
belief this has a negative reflection not only in the work-
ing population (however, the effect in this group seems 
to be the strongest). Children taking cetirizine could have 
a problem with learning and with concentration at school, 
resulting both from antihistamine activity and also from 
anticholinergic action of that drug. This is a common prob-
lem of children, parents and teachers. Sometimes parents 
and teachers are unable to define an underlying reason for 
school problems, and they actually refer to the activity of 
these drugs. 
Falls as a consequence of pharmacotherapy also have 
some importance. Hydroxyzine and cetirizine are close 
after benzodiazepines and opioids on the list of drugs 
increasing the risk of falls in elderly patients.
There are known factors in practice which increase 
the probability of sedation as a result of treatment with 
antihistamines. They are as follows: female gender; very 
young or very old age; hepatic or renal insufficiency; 
heart failure; obesity; hypothyroidism; hypotension; de-
hydration; slow acetylator phenotype. 
According to reported data, pharmacological aspects 
of drugs’ activity clearly translate into clinical activity, so 
they have to be taken into account even during choice 
of symptomatic drugs, including antihistamines. The ad-
verse events profile and interactions of antihistamines 
constitute important criteria of their choice in clinical 
practice. Failure to take this into consideration during 
combined therapy could lead to complications of allergic 
disease management.
Bilastine shows the lowest risk of interactions with 
other drugs as compared with different antihistamines, 
which is associated with its pharmacokinetic and phar-
macodynamic profile [46–58].
Antihistamines and immune system. Preliminary 
results of a study evaluating mechanisms of 
anti-inflammatory action of bilastine
For a long time, several actions of antihistamines 
have been attributed to their putative anti-inflammatory 
features, not directly associated with the histamine re-
ceptor. The majority of those studies were conducted 
in vitro and demonstrated smaller or greater ability of 
antihistamines to, among other things, decrease the ex-
pression of adhesive molecules on the surface of endo-
thelial cells as well as epithelium in the upper and lower 
respiratory tract, reduce eosinophilia in tissues involved 
in the allergic inflammatory process, shorten eosinophil 
survival time, decrease expression of inflammatory cyto-
kines (IL-1β, IL-4, IL-6, IL-7, IL-8, GM-CSF), inhibit release 
of metalloproteinases, reduce oxidative stress and de-
crease replication of rhinoviruses in epithelial cells in the 
respiratory tract. A recent study performed by Krause 
et al. [15] showed in a clinical setting that use of bilas-
tine in a four-fold higher dose as compared to a standard 
dose in patients with cold urticaria led to a significant 
decline of IL-6 and IL-8 concentrations assessed after 
skin microdialysis a few hours after a provocation test 
with cold. This study confirmed in vivo anti-inflammatory 
activity of bilastine; however, it did not identify either the 
source of cytokines’ release or their further influence on 
the immune response. Therefore, we set out to perform 
a more precise assessment of the effects of bilastine on 
different arms of the immune response. We analysed 
the effects of different bilastine concentrations on such 
crucial orchestrators of the immune response as differ-
ent subpopulations of monocytes that are precursors 
of macrophages and dendritic cells and different sub-
populations of CD4+ and CD8+ lymphocytes with either 
regulatory or effector potency. Currently, our large-scale 
basic research is being conducted, evaluating the effect 
of both standard and higher doses of bilastine on pheno-
type as well as functional potential of above-mentioned 
subpopulations of immune cells. The current studies on 
bilastine are among the first such comprehensive trials 
to evaluate the effects of antihistamines’ activity on dif-
ferent elements of cell-mediated immunity. The results 
of these studies will give a chance to more precisely 
assess immunomodulatory activity of bilastine, and in 
consequence contribute to better understanding of its 
mechanisms of action in management of such complex 
inflammatory diseases as chronic urticaria.
Antihistamines in paediatric patients and 
patients with asthma
The second generation antihistamines that are cur-
rently available and the most frequently used fail to meet 
all expectations of paediatricians and allergologists, es-
pecially in terms of safety and adverse events. Moreover, 
not all formulations of these drugs are acceptable for 
children. An ideal oral antihistamine of the second gen-
eration dedicated to paediatric patients should meet the 
following criteria [59–61]:
• Very high selectivity against the H1 receptor (lack of 
extra-receptor activity).
• Fast onset of action.
• Long biological half-time (possibility to administer 
once a day).
• Registration for patients aged 0–18 years (the same 
drug in all age groups, availability of different forms 
of the drug).
• Very good tolerability.
Indications for the use of antihistamines in children 
are generally similar to indications in adults. However, 
there is not such strong evidence for some indications 
in this population as in adults. The first generation an-
tihistamines are not indicated in children due to many 
adverse events connected to activity of these drugs 
against other than H1 receptors in peripheral tissues’ 
(muscarinic, α-adrenergic and serotonin receptors) and 
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H1 receptors in CNS, or cardiac ion channels [62]. A few 
years ago Schad and Skoner summarized the role and 
position of antihistamines for use in children [63]. In this 
systemic review of indications for using antihistamines 
in children, the authors emphasised that the strongest 
recommendations for antihistamines were established 
for allergic rhinitis and allergic conjunctivitis as well as 
urticaria (evidence category I, strength of recommenda-
tion A). Slightly weaker recommendations are for allergic 
conjunctivitis and mosquito bites or eosinophilic cellulitis 
(Wells’ syndrome) (evidence category I, strength of rec-
ommendation B). Other considered or possible indica-
tions, such as asthma or otitis media, failed to receive 
positive recommendations in this review. Benedictis et al. 
presented a similar statement [64]. 
Allergic rhinitis and allergic conjunctivitis 
In light of the ARIA 2008 and ARIA 2010 documents, 
the second generation antihistamines (oral or intranasal) 
are the drugs of first line treatment of periodic allergic 
rhinitis of mild or moderate/severe clinical course and 
mild chronic allergic rhinitis with evidence of strength 
of recommendation A [1, 7]. Antihistamines are also 
a component of therapy of chronic allergic rhinitis of 
moderate/severe clinical course as an add-on drug to 
nasal glucocorticosteroids [7]. The second generation 
antihistamines could also be administered in paediatric 
patients over 12 years old – in combination with nasal 
glucocorticosteroids [65].
Urticaria
In light of two current consensuses of combined 
groups of experts from several organizations (EAACI, 
Ga2LEN, EDF, WAO and/or UNEV), each case of urticaria 
in children should be treated with modern second gen-
eration antihistamines (strong recommendation, high 
strength of evidence), and in chronic urticaria they are 
even the drugs of choice [14, 66]. When clinical symp-
toms remain for over 2 weeks, the second generation 
antihistamines should be administered in a two-to-four 
times higher dose. When despite such management the 
symptoms still persist, it should be considered to add 
a drug from another therapeutic class (as in adults) [14] 
or to exchange one antihistamine of the second genera-
tion for another [62]. The second generation antihista-
mines should be administered in the lowest effective 
dose but not on demand (strong recommendation, high 
strength of evidence) [14].
Food allergy
Antihistamines could immediately reduce clini-
cal symptoms and decrease the severity of the clinical 
course of some food allergy reactions in children [67]. 
However, this recommendation is very weak.
Allergic conjunctivitis
There is a reasonable basis to use antihistamines in 
the treatment of allergic conjunctivitis in children [68]; 
however, there is little reliable evidence of efficacy in this 
indication. Despite this, the antihistamines of the first 
and the second generations are commonly used by pae-
diatricians in this disease, although as a supplementary 
therapy only [69, 70]. The first generation antihistamines 
(with sedative and anti-itching activity) could be helpful 
in children with sleep disorders due to pruritus and in 
severe forms of allergic conjunctivitis [71]. Some antihis-
tamines of the generation reduce skin inflammations, 
too [72].
Anaphylaxis
Antihistamines blocking H1 and/or H2 receptors are 
not the drugs of choice in anaphylaxis, and should not be 
used in monotherapy [73]. The antihistamines could be 
helpful in management of children with anaphylaxis as 
a second or third treatment line [74]. The intramuscular 
administration of the first generation antihistamines (e.g. 
clemastine or antazoline) could be considered – depending 
on the response to adrenaline (the first line drug), corti-
costeroids and salbutamol (the second line treatment) as 
well as the recent clinical status of the child [75].
Primary mast cell activation syndromes
There are no reliable studies in children, especially 
with the second generation antihistamines, although 
these drugs are used in clinical practice [76].
Bilastine in children
As of today, we only have studies regarding pharma-
cokinetics, pharmacodynamics, safety and tolerability of 
bilastine in children. The first trial showed that bilastine 
in the dose of 10 mg used in children aged 2–12 gave 
the same (equivalent) exposure as the dose of 20 mg in 
adults [77]. The second study, in children aged below 12 
with allergic rhinoconjunctivitis or with chronic urticaria, 
indicated safety and tolerability (similar to placebo) of 
bilastine in the dose of 10 mg used for 12 weeks [44].
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